DOP2015000221A - Agentes quelantes de precursores de producto final de glicacion avanzada (age) - Google Patents

Agentes quelantes de precursores de producto final de glicacion avanzada (age)

Info

Publication number
DOP2015000221A
DOP2015000221A DO2015000221A DO2015000221A DOP2015000221A DO P2015000221 A DOP2015000221 A DO P2015000221A DO 2015000221 A DO2015000221 A DO 2015000221A DO 2015000221 A DO2015000221 A DO 2015000221A DO P2015000221 A DOP2015000221 A DO P2015000221A
Authority
DO
Dominican Republic
Prior art keywords
agents
chemical precursors
age
disease
glication
Prior art date
Application number
DO2015000221A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus Besev
Robert J Miller
Andrew T Papoulis
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of DOP2015000221A publication Critical patent/DOP2015000221A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
DO2015000221A 2013-03-15 2015-09-08 Agentes quelantes de precursores de producto final de glicacion avanzada (age) DOP2015000221A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
DOP2015000221A true DOP2015000221A (es) 2015-12-15

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000221A DOP2015000221A (es) 2013-03-15 2015-09-08 Agentes quelantes de precursores de producto final de glicacion avanzada (age)

Country Status (24)

Country Link
US (2) US20160024233A1 (https=)
EP (1) EP2968403A1 (https=)
JP (4) JP2016512830A (https=)
KR (1) KR20150130492A (https=)
CN (1) CN105188718A (https=)
AR (1) AR095593A1 (https=)
AU (2) AU2014235500A1 (https=)
BR (1) BR112015023404A8 (https=)
CA (1) CA2906501A1 (https=)
CL (1) CL2015002624A1 (https=)
CR (1) CR20150545A (https=)
DO (1) DOP2015000221A (https=)
EA (1) EA201591733A1 (https=)
HK (1) HK1220607A1 (https=)
IL (1) IL241406A0 (https=)
MA (1) MA38487A1 (https=)
MX (1) MX2015012843A (https=)
PE (1) PE20151766A1 (https=)
PH (1) PH12015502019A1 (https=)
SG (2) SG10201707590XA (https=)
TN (1) TN2015000390A1 (https=)
TW (1) TW201521744A (https=)
UY (1) UY35441A (https=)
WO (1) WO2014150873A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
CN111405870A (zh) * 2017-08-31 2020-07-10 西托索尔本茨公司 从体液中降低晚期糖基化终末产物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
AU2005214971A1 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
WO2011106542A2 (en) * 2010-02-24 2011-09-01 Relypsa, Inc. Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
IL241406A0 (en) 2015-11-30
KR20150130492A (ko) 2015-11-23
EP2968403A1 (en) 2016-01-20
WO2014150873A1 (en) 2014-09-25
JP2016512830A (ja) 2016-05-09
CA2906501A1 (en) 2014-09-25
SG10201707590XA (en) 2017-11-29
US20180265613A1 (en) 2018-09-20
PE20151766A1 (es) 2015-12-11
PH12015502019A1 (en) 2016-01-11
EA201591733A1 (ru) 2016-01-29
US20160024233A1 (en) 2016-01-28
JP2018135365A (ja) 2018-08-30
MA38487A1 (fr) 2017-12-29
BR112015023404A8 (pt) 2019-12-03
TW201521744A (zh) 2015-06-16
JP2022037143A (ja) 2022-03-08
MX2015012843A (es) 2016-08-08
UY35441A (es) 2014-10-31
CR20150545A (es) 2015-12-01
BR112015023404A2 (pt) 2017-07-18
HK1220607A1 (zh) 2017-05-12
AR095593A1 (es) 2015-10-28
TN2015000390A1 (en) 2017-01-03
CL2015002624A1 (es) 2016-03-11
JP2020055850A (ja) 2020-04-09
CN105188718A (zh) 2015-12-23
AU2019201259A1 (en) 2019-03-14
SG11201506413PA (en) 2015-09-29
AU2014235500A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
TW201613901A (en) New compounds
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
ECSP14024526A (es) Derivados bicíclicos de pirazinona
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
ECSP14017586A (es) Derivados de tetrahidro-quinazolinona
CL2015002897A1 (es) Inhibidores de bace1
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
DOP2015000221A (es) Agentes quelantes de precursores de producto final de glicacion avanzada (age)
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas